BioNTech’s Bold Gamble: The Quest Beyond COVID and Into the Depths of Cancer Research
BioNTech is pivoting from COVID-19 vaccines to innovative cancer treatments, leveraging mRNA technology to enhance immune system responses against cancer cells, with a target for market approval by 2026. Financial…